75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival data (75% vs. 60%, p = 0.034) Updated clinical efficacy data being added to regulatory dossiers as Company seeks early market authorizations in U.S., U.K., Europe and Australia in 2nd half of 2026 EMA and Australia TGA (TGA) alignment achieved on early Q4-202
Read Full ArticleThis article was originally published on newsfilecorp. Click the button above to read the complete article.
